https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2025-03-04 / Cancers (Basel) 2025 Mar;17(5)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2025-03-04 / Cancers (Basel) 2025 Mar;17(5)2025-03-04 00:00:002025-03-17 07:36:12The Complexity of Malignant Glioma Treatment
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2025-01-23 / J Hematol Oncol 2025 Jan;18(1):9
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2025-01-23 / J Hematol Oncol 2025 Jan;18(1):92025-01-23 00:00:002025-01-23 00:00:00WT1-mRNA dendritic cell vaccination of patients with glioblastoma multiforme, malignant pleural mesothelioma, metastatic breast cancer, and other solid tumors: type 1 T-lymphocyte responses are associated with clinical outcome
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2024-12-23 / Clin Transl Oncol 2024 Dec;
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2024-12-23 / Clin Transl Oncol 2024 Dec;2024-12-23 00:00:002024-12-23 00:00:00Autologous tumor lysate-loaded dendritic cell vaccination in glioblastoma patients: a systematic review of literature
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2024-12-17 / Cancers (Basel) 2024 Dec;16(24)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2024-12-17 / Cancers (Basel) 2024 Dec;16(24)2024-12-17 00:00:002024-12-17 00:00:00Retrospective Analysis of HLA Class II-Restricted Neoantigen Peptide-Pulsed Dendritic Cell Vaccine for Breast Cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2024-11-30 / Vet World 2024 Nov;17(11):2688-2693
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2024-11-30 / Vet World 2024 Nov;17(11):2688-26932024-11-30 00:00:002024-11-30 00:00:00The oncolytic effect of Newcastle disease virus attenuated AMHA1 strain against digestive system tumors
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2024-11-21 / Cancers (Basel) 2024 Nov;16(23)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2024-11-21 / Cancers (Basel) 2024 Nov;16(23)2024-11-21 00:00:002024-11-21 00:00:00The Synergy of Thermal and Non-Thermal Effects in Hyperthermic Oncology
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2024-11-04 / Expert Opin Biol Ther 2024 Nov;24(11):1245-1259
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2024-11-04 / Expert Opin Biol Ther 2024 Nov;24(11):1245-12592024-11-04 00:00:002025-02-25 11:05:42The future of cellular therapy for the treatment of renal cell carcinoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2024-10-29 / Int Immunopharmacol 2024 Dec;143(Pt 2):113481
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2024-10-29 / Int Immunopharmacol 2024 Dec;143(Pt 2):1134812024-10-29 00:00:002024-10-29 00:00:00Synergistic Anti-Tumor Effects of Newcastle Disease Virus and Doxorubicin: Evidence from A Murine Breast Cancer Model
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2024-10-28 / Mol Ther Oncol 2024 Dec;32(4):200898
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2024-10-28 / Mol Ther Oncol 2024 Dec;32(4):2008982024-10-28 00:00:002024-10-28 00:00:00Newcastle disease virus harboring the PTEN gene inhibits pancreatic cancer growth by inhibiting PI3K/AKT/mTOR signaling and activating apoptosis
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2024-10-28 / Mol Ther Oncol 2024 Dec;32(4):200899
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2024-10-28 / Mol Ther Oncol 2024 Dec;32(4):2008992024-10-28 00:00:002024-10-28 00:00:00IL-12 encoding oNDV synergizes with CAR-T cells in orthotopic models of non-small cell lung cancer
